PubRank

Frederick M Hecht

Author PubWeight™ 185.91‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006 24.38
2 The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010 9.61
3 Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood 2004 7.09
4 Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med 2008 5.94
5 Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. AIDS 2003 5.28
6 Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis 2005 4.27
7 Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med 2010 4.07
8 Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002 4.02
9 Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis 2009 3.91
10 Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol 2004 3.58
11 HIV testing within at-risk populations in the United States and the reasons for seeking or avoiding HIV testing. J Acquir Immune Defic Syndr 2002 3.43
12 CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nat Immunol 2007 3.31
13 CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat Med 2008 2.94
14 Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells. J Virol 2009 2.51
15 Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses. J Virol 2006 2.50
16 Changes in stress, eating, and metabolic factors are related to changes in telomerase activity in a randomized mindfulness intervention pilot study. Psychoneuroendocrinology 2011 2.37
17 Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis 2013 2.23
18 Development of a new less-sensitive enzyme immunoassay for detection of early HIV-1 infection. J Acquir Immune Defic Syndr 2003 2.21
19 The detection of acute HIV infection. J Infect Dis 2010 2.14
20 Frequent detection of the parvoviruses, PARV4 and PARV5, in plasma from blood donors and symptomatic individuals. Transfusion 2007 2.02
21 Differential persistence of transmitted HIV-1 drug resistance mutation classes. J Infect Dis 2011 1.90
22 Elevations in IL-10, TNF-alpha, and IFN-gamma from the earliest point of HIV Type 1 infection. AIDS Res Hum Retroviruses 2006 1.83
23 T cell responses to human endogenous retroviruses in HIV-1 infection. PLoS Pathog 2007 1.70
24 Independent assessment of candidate HIV incidence assays on specimens in the CEPHIA repository. AIDS 2014 1.67
25 Seroreversion in subjects receiving antiretroviral therapy during acute/early HIV infection. Clin Infect Dis 2006 1.65
26 The relation between symptoms, viral load, and viral load set point in primary HIV infection. J Acquir Immune Defic Syndr 2007 1.62
27 Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden. J Infect Dis 2011 1.59
28 Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS 2004 1.53
29 Mindfulness Intervention for Stress Eating to Reduce Cortisol and Abdominal Fat among Overweight and Obese Women: An Exploratory Randomized Controlled Study. J Obes 2011 1.50
30 Rapid progressing allele HLA-B35 Px restricted anti-HIV-1 CD8+ T cells recognize vestigial CTL epitopes. PLoS One 2010 1.49
31 FOXP3 expressing CD127lo CD4+ T cells inversely correlate with CD38+ CD8+ T cell activation levels in primary HIV-1 infection. J Leukoc Biol 2007 1.47
32 Human immunodeficiency virus type 1 Vpr induces DNA replication stress in vitro and in vivo. J Virol 2006 1.47
33 Conferral of enhanced natural killer cell function by KIR3DS1 in early human immunodeficiency virus type 1 infection. J Virol 2008 1.47
34 Human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T(EMRA) cells in early infection are linked to control of HIV-1 viremia and predict the subsequent viral load set point. J Virol 2007 1.46
35 Tolerability and efficacy of PI versus NNRTI-based regimens in subjects receiving HAART during acute or early HIV infection. J Acquir Immune Defic Syndr 2009 1.46
36 Absolute or total lymphocyte count as a marker for the CD4 T lymphocyte criterion for initiating antiretroviral therapy. AIDS 2003 1.44
37 Body awareness: construct and self-report measures. PLoS One 2009 1.43
38 Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009. PLoS One 2010 1.39
39 Initiation of antiretroviral therapy at higher nadir CD4+ T-cell counts is associated with reduced arterial stiffness in HIV-infected individuals. AIDS 2010 1.36
40 CD56negCD16⁺ NK cells are activated mature NK cells with impaired effector function during HIV-1 infection. Retrovirology 2013 1.30
41 Sequential broadening of CTL responses in early HIV-1 infection is associated with viral escape. PLoS One 2007 1.30
42 Hematopoietic precursor cells isolated from patients on long-term suppressive HIV therapy did not contain HIV-1 DNA. J Infect Dis 2012 1.30
43 Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection. J Infect Dis 2004 1.27
44 Frequent methamphetamine use is associated with primary non-nucleoside reverse transcriptase inhibitor resistance. AIDS 2007 1.26
45 Loss of T cell responses following long-term cryopreservation. J Immunol Methods 2007 1.23
46 Synergy or independence? Deciphering the interaction of HLA Class I and NK cell KIR alleles in early HIV-1 disease progression. PLoS Pathog 2007 1.22
47 The association of CD4+ T-cell counts and cardiovascular risk in treated HIV disease. AIDS 2012 1.21
48 Strong human endogenous retrovirus-specific T cell responses are associated with control of HIV-1 in chronic infection. J Virol 2011 1.19
49 Symptom management with massage and acupuncture in postoperative cancer patients: a randomized controlled trial. J Pain Symptom Manage 2007 1.16
50 Similar changes in plasmacytoid dendritic cell and CD4 T-cell counts during primary HIV-1 infection and treatment. AIDS 2006 1.16
51 Nucleic acid amplification testing for diagnosis of acute HIV infection: has the time come? AIDS 2005 1.14
52 The effects of early antiretroviral therapy and its discontinuation on the HIV-specific antibody response. AIDS Res Hum Retroviruses 2006 1.11
53 Mindfulness-based stress reduction for HIV treatment side effects: a randomized, wait-list controlled trial. J Pain Symptom Manage 2011 1.09
54 Stimulant use is associated with immune activation and depleted tryptophan among HIV-positive persons on anti-retroviral therapy. Brain Behav Immun 2008 1.08
55 HIV-1 Vif adaptation to human APOBEC3H haplotypes. Cell Host Microbe 2013 1.07
56 Clinical presentation and diagnosis of primary HIV-1 infection. Curr Opin HIV AIDS 2008 1.04
57 Lower cytokine secretion ex vivo by natural killer T cells in HIV-infected individuals is associated with higher CD161 expression. AIDS 2009 1.03
58 High CD8+ T cell activation marks a less differentiated HIV-1 specific CD8+ T cell response that is not altered by suppression of viral replication. PLoS One 2009 1.02
59 A yoga intervention for type 2 diabetes risk reduction: a pilot randomized controlled trial. BMC Complement Altern Med 2014 1.01
60 Randomized, controlled trial of breath therapy for patients with chronic low-back pain. Altern Ther Health Med 2005 0.99
61 Expansion of CD1d-restricted NKT cells in patients with primary HIV-1 infection treated with interleukin-2. Blood 2005 0.98
62 Elevated frequency of gamma interferon-producing NK cells in healthy adults vaccinated against influenza virus. Clin Vaccine Immunol 2007 0.97
63 Physicians' communication with patients about adherence to HIV medication in San Francisco and Copenhagen: a qualitative study using Grounded Theory. BMC Health Serv Res 2006 0.96
64 Programmed death-1 expression on CD4⁺ and CD8⁺ T cells in treated and untreated HIV disease. AIDS 2014 0.95
65 Immune reconstitution of CD56(dim) NK cells in individuals with primary HIV-1 infection treated with interleukin-2. J Infect Dis 2008 0.94
66 Yoga breathing for cancer chemotherapy-associated symptoms and quality of life: results of a pilot randomized controlled trial. J Altern Complement Med 2012 0.93
67 The prognosis of acute low back pain in primary care in the United States: a 2-year prospective cohort study. Spine (Phila Pa 1976) 2012 0.93
68 Characterization of human immunodeficiency virus type 1 populations containing CXCR4-using variants from recently infected individuals. AIDS Res Hum Retroviruses 2009 0.92
69 Transcriptional errors in human immunodeficiency virus type 1 generate targets for T-cell responses. Clin Vaccine Immunol 2009 0.92
70 Expansion of CD8+ T cells lacking Sema4D/CD100 during HIV-1 infection identifies a subset of T cells with decreased functional capacity. Blood 2011 0.91
71 IL-2 immunotherapy to recently HIV-1 infected adults maintains the numbers of IL-17 expressing CD4+ T (T(H)17) cells in the periphery. J Clin Immunol 2010 0.89
72 Comparison of algorithms that interpret genotypic HIV-1 drug resistance to determine the prevalence of transmitted drug resistance. AIDS 2008 0.89
73 The calm mouse: an animal model of stress reduction. Mol Med 2012 0.89
74 Acute HIV-1 infection: what's new? Where are we going? J Infect Dis 2010 0.88
75 Acute low back pain and primary care: how to define recovery and chronification? Spine (Phila Pa 1976) 2011 0.87
76 Expansion of CD7(low) and CD7(negative) CD8 T-cell effector subsets in HIV-1 infection: correlation with antigenic load and reversion by antiretroviral treatment. Blood 2004 0.87
77 HIV disease progression correlates with the generation of dysfunctional naive CD8(low) T cells. Blood 2011 0.87
78 Hematopoietic cell transplant and use of massage for improved symptom management: results from a pilot randomized control trial. Evid Based Complement Alternat Med 2012 0.86
79 Trans-activation, post-transcriptional maturation, and induction of antibodies to HERV-K (HML-2) envelope transmembrane protein in HIV-1 infection. Retrovirology 2014 0.86
80 The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection. J Infect Dis 2010 0.85
81 Combination of immune and viral factors distinguishes low-risk versus high-risk HIV-1 disease progression in HLA-B*5701 subjects. J Virol 2012 0.85
82 Increased HLA-DR expression on peripheral blood monocytes in subsets of subjects with primary HIV infection is associated with elevated CD4 T-cell apoptosis and CD4 T-cell depletion. J Acquir Immune Defic Syndr 2002 0.85
83 Functional avidity and IL-2/perforin production is linked to the emergence of mutations within HLA-B*5701-restricted epitopes and HIV-1 disease progression. J Immunol 2014 0.83
84 Resistance testing in drug-naive HIV-infected patients: is it time? Clin Infect Dis 2005 0.83
85 Viral load criteria and threshold optimization to improve HIV incidence assay characteristics. AIDS 2016 0.83
86 Greater reversal of CD4+ cell abnormalities and viral load reduction after initiation of antiretroviral therapy with zidovudine, lamivudine, and nelfinavir before complete HIV type 1 seroconversion. AIDS Res Hum Retroviruses 2003 0.82
87 Changes in HIV testing after implementation of name-based HIV case surveillance in New Mexico. Am J Public Health 2002 0.82
88 HIV-1 infection abrogates CD8+ T cell mitogen-activated protein kinase signaling responses. J Virol 2011 0.82
89 Persistence of integrated HIV DNA in CXCR3 + CCR6 + memory CD4+ T cells in HIV-infected individuals on antiretroviral therapy. AIDS 2016 0.82
90 HIV-Selectest enzyme immunoassay and rapid test: ability to detect seroconversion following HIV-1 infection. J Clin Microbiol 2009 0.82
91 Interleukin-2 therapy restores CD8 cell non-cytotoxic anti-HIV responses in primary infection subjects receiving HAART. AIDS 2004 0.82
92 Select host restriction factors are associated with HIV persistence during antiretroviral therapy. AIDS 2015 0.81
93 Immune escape mutations detected within HIV-1 epitopes associated with viral control during treatment interruption. J Acquir Immune Defic Syndr 2010 0.81
94 Targeting of conserved gag-epitopes in early HIV infection is associated with lower plasma viral load and slower CD4(+) T cell depletion. AIDS Res Hum Retroviruses 2013 0.80
95 Cortisol patterns are associated with T cell activation in HIV. PLoS One 2013 0.80
96 CD8+ cell anti-HIV activity rapidly increases upon discontinuation of early antiretroviral therapy. J Clin Immunol 2009 0.79
97 Newly diagnosed HIV infection. N Engl J Med 2006 0.78
98 HIV-1-specific T Cell-dependent natural killer (NK) cell activation: major contribution by NK cells to interferon-gamma production in response to HIV-1 antigens. AIDS Res Hum Retroviruses 2009 0.78
99 Longitudinal characterization of depression and mood states beginning in primary HIV infection. AIDS Behav 2014 0.78
100 Greater CD4 T-cell gains after one year of antiretroviral therapy are associated with lower HIV-1 pol replication capacity. AIDS 2006 0.78
101 Correlating traditional Ayurvedic and modern medical perspectives on cancer: results of a qualitative study. J Altern Complement Med 2013 0.78
102 Quantitative longitudinal analysis of T cell receptor repertoire expression in HIV-infected patients on antiretroviral and interleukin-2 therapy. AIDS Res Hum Retroviruses 2007 0.77
103 Potential herpesvirus interaction during HIV type 1 primary infection. AIDS Res Hum Retroviruses 2005 0.77
104 Differential expression of CD96 surface molecule represents CD8⁺ T cells with dissimilar effector function during HIV-1 infection. PLoS One 2012 0.75
105 Correction: Rapid Progressing Allele HLA-B35 Px Restricted Anti-HIV-1 CD8+ T Cells Recognize Vestigial CTL Epitopes. PLoS One 2016 0.75
106 Immunologic profiles distinguish aviremic HIV-infected adults. AIDS 2016 0.75